Cat. No.: HY-14658

Thalidomide

26 Cited Publications

Avis client

Based on 26 publication(s) in Google Scholar

Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.98%
CAS No.: 50-35-1
Formule: C₁₃H₁₀N₂O₄
Masse moléculaire:258.23

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Thalidomide Chemical Structure

CAS No.: 50-35-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (26)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Cereblon

Voir tous les produits spécifiques à Isoform Ligands for E3 Ligase :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	176.11 μM Compound: Tha	Antiproliferative activity against mouse 4T1 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 37376788]
DLD-1	IC₅₀	>50 μM Compound: Thalidomide	Cytotoxicity against human DLD1 cells by MTT assay Cytotoxicity against human DLD1 cells by MTT assay	[PMID: 19394719]
EA.hy 926	IC₅₀	200 μM Compound: Thalidomide	Antiproliferative activity against human EAhy926 cells Antiproliferative activity against human EAhy926 cells	[PMID: 19103485]
Ehrlich	IC₅₀	0.26 nM Compound: Thalidomide	Cytotoxicity against mouse Ehrlich cells assessed as cell growth inhibition incubated for 3 hrs by trypan blue exclusion assay Cytotoxicity against mouse Ehrlich cells assessed as cell growth inhibition incubated for 3 hrs by trypan blue exclusion assay	[PMID: 34710743]
Ehrlich	IC₅₀	2.6 x 10^-4 μM Compound: Thalidomide	Cytotoxicity against mouse Ehrlich cells assessed as cell growth inhibition incubated for 3 hrs by trypan blue exclusion assay Cytotoxicity against mouse Ehrlich cells assessed as cell growth inhibition incubated for 3 hrs by trypan blue exclusion assay	[PMID: 34710743]
HeLa	IC₅₀	2.04 μM Compound: thalidomide	Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation	[PMID: 17845850]
HL-60	IC₅₀	>50 μM Compound: Thalidomide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19394719]
HT-29	IC₅₀	>50 μM Compound: Thalidomide	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19394719]
HUVEC	IC₅₀	>50 μM Compound: Thalidomide	Cytotoxicity against HUVEC by MTT assay Cytotoxicity against HUVEC by MTT assay	[PMID: 19394719]
KMS-12-PE	IC₅₀	>75 μM Compound: 1	Antiproliferative activity against human KMS-12-PE cells assessed as inhibition of cell proliferation incubated for 48 hrs by CellTiter Glo luminescence based MTT assay Antiproliferative activity against human KMS-12-PE cells assessed as inhibition of cell proliferation incubated for 48 hrs by CellTiter Glo luminescence based MTT assay	[PMID: 36476642]
MOLP-8	IC₅₀	>75 μM Compound: 1	Antiproliferative activity against human MOLP8 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CellTiter Glo luminescence based MTT assay Antiproliferative activity against human MOLP8 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CellTiter Glo luminescence based MTT assay	[PMID: 36476642]
PBMC	IC₅₀	77 μM Compound: 3	Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA	[PMID: 23168019]
PBMC	IC₅₀	~ 200 μM Compound: Thalidomide	Inhibition of LPS stimulated Tumor Necrosis Factor-alpha (TNF-alpha) release by human PBMC Inhibition of LPS stimulated Tumor Necrosis Factor-alpha (TNF-alpha) release by human PBMC	[PMID: 9873600]
ST486	IC₅₀	>50 μM Compound: Thalidomide	Cytotoxicity against human ST486 cells by MTT assay Cytotoxicity against human ST486 cells by MTT assay	[PMID: 19394719]
T-cell	EC₅₀	>10 μM Compound: 3	Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA	[PMID: 23168019]
THP-1	IC₅₀	>2 nM Compound: 1	Inhibition of LPS-induced Tumor necrosis factor-alpha production (TNF-alpha) in THP-1 cells Inhibition of LPS-induced Tumor necrosis factor-alpha production (TNF-alpha) in THP-1 cells	[PMID: 9871710]
U-937	IC₅₀	>500 μM Compound: Thalidomide	Inhibition of PDE4 enzyme from U937 cells Inhibition of PDE4 enzyme from U937 cells	[PMID: 9873600]
WI-38	IC₅₀	>100 μg/mL Compound: 10 (Thalidomide)	The cytotoxicity assessed using human embryonic lung fibroblast WI-38 cells. The cytotoxicity assessed using human embryonic lung fibroblast WI-38 cells.	[PMID: 9288167]

In Vitro

Thalidomide has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties, and targets cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ～250 nM^[1].
Thalidomide (50 μg/mL) potentiates the anti-tumor activity of Icotinib against the proliferation of both PC9 and A549 cells, and this effect is correlated with apoptosis and cell migration. In addition, Thalidomide and Icotinib inhibits the EGFR and VEGF-R2 pathways in PC9 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Thalidomide (100 mg/kg, p.o.) inhibits the collagen deposition, down-regulates the mRNA expression level of α-SMA and collagen I, and significantly reduces the pro-inflammatory cytokines in RILF mice. Thalidomide alleviates RILF via suppression of ROS and down-regulation of TGF-β/Smad pathway dependent on Nrf2 status^[2].
Thalidomide (200 mg/kg, p.o.) combined with Icotinib shows synergistic anti-tumor effects in nude mice bearing PC9 cells, suppressing tumor growth and promoting tumor death^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 50-35-1
Appearance Solid
Masse moléculaire 258.23
Formule C₁₃H₁₀N₂O₄
Color White to off-white
SMILES

O=C1N(C2CCC(NC2=O)=O)C(C3=CC=CC=C31)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (26)

All WB

Sort by:

Journal Impact Factor

Nat Cancer

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. [Abstract]

2022 May;3(5):595-613. PMID: 35534777

Thalidomide purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 May;3(5):595-613. [Abstract]

Western blot analysis for IKAROS, CK1α and MENIN protein following treatment of MV4;11 human MLL-r AML cell line for 5 hours with increasing doses of Thalidomide, lenalidomide, Pomalidomide and iberdomide (10,100, 1000 nM), using ACTIN as a loading control.
Cell Stem Cell

Human PSC-derived sinoatrial node-cardiac plexus assembloids model innervation-associated maturation of pacemaker systems. [Abstract]

2026 May 15:S1934-5909(26)00158-X. PMID: 42143017
Nat Commun

Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis. [Abstract]

2022 Sep 10;13(1):5324. PMID: 36088459

Thalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 10;13(1):5324. [Abstract]

Western immunoassays used to monitor changes in BNC2 levels in LX2 cells treated with 1 μM pomalidomide (Pom.), thalidomide (Thal.), CC-885, Iberdomide (Iber.) or vehicle for 24 h.
Nat Commun

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. [Abstract]

2017 May 22:8:15398. PMID: 28530236

Thalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 May 22:8:15398. [Abstract]

HEK293T cells are treated with 50 μg/mL Cycloheximide and increasing concentrations of Lenalidomide, Thalidomide or with DMSO, and cells are incubated for 6 h. ZFP91 and GAPDH levels are detected using anti-ZFP91 or anti-GAPDH immunoblotting.
Acta Pharm Sin B

Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis. [Abstract]

2024 Aug;14(8):3493-3512. PMID: 39220878
Aggregate

2025 Oct 12.
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Rep Med

STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. [Abstract]

2024 Mar 19;5(3):101472. PMID: 38508140
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Hazard Mater

A new mechanism for ubiquitination in polystyrene nanoplastic-induced spatial cognitive dysfunction through microglial activation-induced apoptosis of neurons. [Abstract]

2026 Mar 1:505:141552. PMID: 41734560
Acta Pharmacol Sin

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. [Abstract]

2020 Sep;41(9):1246-1254. PMID: 32210356
J Med Chem

Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. [Abstract]

2025 Oct 23;68(20):21172-21186. PMID: 41066447
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Sci Rep

Identifying novel aging-related diagnostic and prognostic models and aging-targeted drugs for sepsis patients. [Abstract]

2024 Dec 28;14(1):31445. PMID: 39732977
Oncol Rep

Synergistic effects of thalidomide and cisplatin are mediated via the PI3K/AKT and JAK1/STAT3 signaling pathways in cervical cancer. [Abstract]

2022 Oct;48(4):169. PMID: 35920185
ACS Pharmacol Transl Sci

General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex. [Abstract]

2021 Feb 26;4(2):941-952. PMID: 33860212
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Food Chem Toxicol

Melatonin attenuates chronic stress-induced hippocampal inflammatory response and apoptosis by inhibiting ADAM17/TNF-α axis. [Abstract]

2022 Nov:169:113441. PMID: 36162616
J Appl Toxicol

Establishment of an in vitro method of rabbit embryo toxicity with toxicokinetics study. [Abstract]

2022 Mar;42(3):380-391. PMID: 34322893
Charles University

2026.
SSRN

2025 Dec 15.
Chemrxiv

2025 Nov 17.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

2025 Jun 19.
bioRxiv

2023 Jun 28.
Elife

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. [Abstract]

2018 Aug 1:7:e38430. PMID: 30067223

Thalidomide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1:7:e38430. [Abstract]

H9 hESC are treated with increasing concentrations of Thalidomide, Lenalidomide, Pomalidomide, or DMSO as a control. Following 24 h of incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.

Thalidomide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1:7:e38430. [Abstract]

Kelly cells are treated with increasing concentrations of Thalidomide and co-treated with 5 μM Bortezomib, 5 μM MLN4924, 0.5 μM MLN7243, or DMSO as a control. Following 24 h incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (387.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8725 mL

19.3626 mL

38.7252 mL

5 mM

0.7745 mL

3.8725 mL

7.7450 mL

10 mM

0.3873 mL

1.9363 mL

3.8725 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 20 mg/mL (77.45 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% Tween-80 in PBS

Solubility: 20 mg/mL (77.45 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[2]

THP-1 cells, A549 cells and KYSE30 cells are cultured in RPMI-1640 Medium supplemented with 10% fetal bovine serum and maintained at 37 °C in an atmosphere of 5% CO₂ and 95% room air. THP-1 cells is irradiated with a single dose of 4 Gy 6-MV X-ray and treated with or without Thalidomide (0.2 μmol/mL)-containing medium for 48 h after radiation. The concentration of Thalidomide is selected based on the preliminary results^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
A total of 24 WT C57BL/6 mice are randomly divided into 4 groups for the experiments (n = 6 in each group): a control group, an irradiated group, a group irradiated along with Thalidomide, and a Thalidomide only group. Based on the preliminary results, 100 mg/kg Thalidomide is used in the experiment. Thalidomide is dissolved in DMSO vehicle. The treatment group receives the indicated dose of Thalidomide in 200  μL by gavage every other day beginning on day 1 for six treatments. The control mice receives 200 μL 0.1% DMSO contained-saline only. The lungs are harvested at 12 weeks after irradiation for the analysis. A total of 20 Nrf2-/- mice are randomly divided into 4 groups for the experiments (n = 5 in each group). The experiment procedures of Nrf2-/- mice are the same as WT C57BL/6 mice. In addition, a total of 30 WT C57BL/6 mice are randomly divided into 5 groups for the subsequent experiments (n = 6 in each group): a control group, an irradiated group, a group irradiated along with CDDO-Me and Thalidomide, a group irradiated along with CDDO-Me, and a group irradiated along with Thalidomide. 600 ng and 100 mg/kg are selected as the dose of CDDO-Me and Thalidomide for the experiment, respectively. The treatment group receives the indicated dose of CDDO-Me or Thalidomide in 200 μL by gavage every other day beginning on day 1 for six times. For the combined group of CDDO-Me and Thalidomide, CDDO-Me is delivered in 200 μL by gavage every other day beginning on day 1 for six treatments. Thalidomide is delivered in 200  μL by gavage every other day beginning on day 2 for six treatments^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512(7512):49-53. [Content Brief]

[2]. Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203. [Content Brief]

[3]. Bian C, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radic Biol Med. 2018 Dec;129:446-453. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8725 mL	19.3626 mL	38.7252 mL	96.8129 mL
	5 mM	0.7745 mL	3.8725 mL	7.7450 mL	19.3626 mL
	10 mM	0.3873 mL	1.9363 mL	3.8725 mL	9.6813 mL
	15 mM	0.2582 mL	1.2908 mL	2.5817 mL	6.4542 mL
	20 mM	0.1936 mL	0.9681 mL	1.9363 mL	4.8406 mL
	25 mM	0.1549 mL	0.7745 mL	1.5490 mL	3.8725 mL
	30 mM	0.1291 mL	0.6454 mL	1.2908 mL	3.2271 mL
	40 mM	0.0968 mL	0.4841 mL	0.9681 mL	2.4203 mL
	50 mM	0.0775 mL	0.3873 mL	0.7745 mL	1.9363 mL
	60 mM	0.0645 mL	0.3227 mL	0.6454 mL	1.6135 mL
	80 mM	0.0484 mL	0.2420 mL	0.4841 mL	1.2102 mL
	100 mM	0.0387 mL	0.1936 mL	0.3873 mL	0.9681 mL

Keywords

Thalidomide

26 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Thalidomide

Ubiquitination Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

E3 Ligase Ligand Library

Non-steroidal Anti-Inflammatory Compound Library

Molecular Glue Compound Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

3D Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Molecular Glue-like Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Thalidomide

Voir tous les produits spécifiques à Isoform Ligands for E3 Ligase

Activité biologique

Chemical Information

Publications (26)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Thalidomide Related Classifications

HY-14658 Related Classifications